Sexually Transmitted Diseases Drug Market Forecast, Trend Analysis & Competition Tracking - Global Industry Insights 2015 to 2031

Sexually Transmitted Diseases Drug Market Revenue Outlook:

The global sexually transmitted diseases drug market was valued at US$ 5.01 Bn in 2020 and is projected to register а САGR of 11.2% by 2031.

Request Covid - 19 Impact

Sexually transmitted diseases (STDs) are also known as sexually transmitted infections. It is an infection passed from one person to another through sexual contact. The contact can be through vaginal, oral, and anal sex. Over thirty viruses, bacteria, and parasites are spread through sexual contact. Eight of the pathogens are linked to the most significant occurrence of sexually transmitted diseases. Of these eight infections, four are now curable: gonorrhea, chlamydia, trichomoniasis, and syphilis. The other 4 are incurable viral infections: hepatitis B, herpes simplex virus (HSV or herpes), HIV, and human papillomavirus (HPV).

Nonetheless, industry players in the global sexually transmitted diseases drug market are now increasing their focus on establishing successful collaborations, acquisitions, and joint venture activities to enhance their respective customer bases. These players are also growing their supply capabilities to meet customer requirements on a local and global scale. This factor, paired with promising industrialization prospects in developing economies of the Asia-Pacific region, such as China, India, Taiwan, Indonesia, etc., are expected to create massive business opportunities for key players over the forecast period.

Classification Of Sexually Transmitted Diseases

To learn more about this report, request for Sample Report

Increasing Prevalence Of Sexually Transmitted Diseases Fueling The Market Growth

Globally the prevalence of sexually transmitted diseases such as Chlamydia, HPV (human papillomavirus), Syphilis, HIV, Gonorrhea, Pubic lice, Trichomonas, Herpes, etc. is increasing rapidly. The prevalence rate of sexually transmitted diseases is more in developing countries. Additionally,  lack of awareness about sexually transmitted diseases and the rising incidences of unprotected sex has contributed to sexually transmitted infections.

• According to World Health Organization (WHO), nearly one million patients suffer from STIs every day. In 2016, WHO estimated approximately 376 million new infections with chlamydia –127 million, gonorrhea – 87 million, syphilis – 6.3 million, and trichomoniasis – 156 million.
• According to WHO recent report, approx. Five hundred million people live with genital HSV (herpes), and an estimated 240 million people suffer from chronic hepatitis B globally.

Lack Of Awareness And Inadequate Reimbursements Scenario Hamper The Market Growth

Lack of knowledge and awareness about sexually transmitted diseases in developing and under-developing countries for adequate prevention and treatment of STI is expected to hamper the global sexually transmitted diseases drug market. The lack of sufficient reimbursements for preventing, diagnosing, and treating STDs in some developing or under-developing countries may hamper the market growth to a certain extent. Improper drug use, poverty, stigma, and unstable housing can minimize STD prevention and care. These factors are expected to hamper market growth.

Government Initiatives

World Health Organization plan for Global Health Sector are:

• By 2030, end the epidemics of tuberculosis, AIDS, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases
• By 2030, reducing the number of deaths and illnesses from hazardous chemicals and air, water, and soil pollution and contamination
• By 2030, minimizing the global maternal mortality ratio to less than 70 per 100,000 live births

Clinical Trial Data For Sexually Transmitted Infection Drug

To learn more about this report, request for Sample Report

Regional Analysis

Why Is Demand For Sexually Transmitted Diseases Drug Market High In The North America Region?

Sexually transmitted infection (STI) has increased in the United States, especially among young (15–24), due to high-risk sexual behavior such as concurrent partners or sex without a condom.

Competitive Landscape

The sexually transmitted diseases drug market landscape appears highly consolidated, with a significant chunk of it being dominated by the U.S. players.

• AbbVie, Inc.
• Bayer Healthcare AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Other Players

Report Scope

• Forecast Period: 2022-2031
• Actual Year: 2021
• Historical Data Available for: 2015-2020

Key Regions Covered

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Segments Covered for Global Sexually Transmitted Diseases Drug Market

Global Sexually Transmitted Diseases Drug Market Segmented by Drug Class

• Chlamydia
• Gonorrhea
• Syphilis
• Genital herpes
• HPV
• HIV / AIDS

Global Sexually Transmitted Diseases Drug Market Segmented by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Medical Stores

To learn more about this report, request for Sample Report